BioCentury | Sep 4, 2019
Preclinical News

Preclinical Quick Takes: NIH's clinical trial practices in preclinical studies, plus Kancera and optimized base editors

...randomization, blinded analysis and reproduction in other labs. Kancera presents first data on CX3CR1 inhibitor Kancera AB...
...Chemokine CX3C motif receptor 1 Mary Romeo, Assistant Editor and Karen Tkach Tuzman, Associate Editor Beam Therapeutics Kancera AB Massachusetts...
BioCentury | Mar 2, 2018
Clinical News

Kancera's KAND567 well tolerated in Phase I

...in markers for hepatic impairment were reported at the twice-daily 800 mg dose of KAND567. Kancera...
...1 (CX3CR1; Fractalkine) from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acturum Life Sciences AB (Sodertalje, Sweden). Kancera AB...
...disease Endpoint: Safety and pharmacokinetics Status: Phase I data Milestone: NA Chris Lieu AZD8797 KAN0440567 Acturum Life Sciences AB AstraZeneca plc Kancera AB KAND567...
BioCentury | Feb 2, 2017
Distillery Therapeutics

Cancer

...IgG1 mAb specific for ROR1, in Phase I testing for refractory chronic lymphocytic leukemia (CLL). Kancera AB...
BioCentury | Oct 24, 2016
Emerging Company Profile

RORing against resistance

...ROR1 inhibitors, including a bispecific protein from Aptevo Therapeutics Inc. and a small molecule from Kancera AB...
...Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Aptevo Therapeutics Inc. (NASDAQ:APVO), Seattle, Wash. Kancera AB...
BioCentury | Jul 30, 2015
Strategy

Neglected Attention

...EU's Seventh Framework Programme and from partners' contributions January 2013 SEtTReND iNovacia AB subsidiary of Kancera AB...
BioCentury | Jan 30, 2014
Distillery Therapeutics

Indication: Cancer

...cell engraftment compared with IgG control. Ongoing studies include developing a humanized antibody targeting ROR1. Kancera AB...
BioCentury | Oct 22, 2012
Emerging Company Profile

Sprint: Quick start in cancer

...2010, Sprint co-founded cancer company Kancera AB and out-licensed the PFKFB3 program to the newco. "Co-founding Kancera...
...will probably seek additional funding from its investors early next year. Companies and Institutions Mentioned Kancera AB...
BioCentury | Oct 8, 2012
Company News

Intellect Neurosciences, Kancera deal

...Intellect partnered with Kancera's iNovacia AB subsidiary to evaluate compounds needed to optimize Intellect's Conjumab-A...
...financial details, while Kancera could not be reached. Intellect Neurosciences Inc. (OTCBB:ILNS), New York, N.Y. Kancera AB...
Items per page:
1 - 8 of 8
BioCentury | Sep 4, 2019
Preclinical News

Preclinical Quick Takes: NIH's clinical trial practices in preclinical studies, plus Kancera and optimized base editors

...randomization, blinded analysis and reproduction in other labs. Kancera presents first data on CX3CR1 inhibitor Kancera AB...
...Chemokine CX3C motif receptor 1 Mary Romeo, Assistant Editor and Karen Tkach Tuzman, Associate Editor Beam Therapeutics Kancera AB Massachusetts...
BioCentury | Mar 2, 2018
Clinical News

Kancera's KAND567 well tolerated in Phase I

...in markers for hepatic impairment were reported at the twice-daily 800 mg dose of KAND567. Kancera...
...1 (CX3CR1; Fractalkine) from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acturum Life Sciences AB (Sodertalje, Sweden). Kancera AB...
...disease Endpoint: Safety and pharmacokinetics Status: Phase I data Milestone: NA Chris Lieu AZD8797 KAN0440567 Acturum Life Sciences AB AstraZeneca plc Kancera AB KAND567...
BioCentury | Feb 2, 2017
Distillery Therapeutics

Cancer

...IgG1 mAb specific for ROR1, in Phase I testing for refractory chronic lymphocytic leukemia (CLL). Kancera AB...
BioCentury | Oct 24, 2016
Emerging Company Profile

RORing against resistance

...ROR1 inhibitors, including a bispecific protein from Aptevo Therapeutics Inc. and a small molecule from Kancera AB...
...Companies and Institutions Mentioned AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Aptevo Therapeutics Inc. (NASDAQ:APVO), Seattle, Wash. Kancera AB...
BioCentury | Jul 30, 2015
Strategy

Neglected Attention

...EU's Seventh Framework Programme and from partners' contributions January 2013 SEtTReND iNovacia AB subsidiary of Kancera AB...
BioCentury | Jan 30, 2014
Distillery Therapeutics

Indication: Cancer

...cell engraftment compared with IgG control. Ongoing studies include developing a humanized antibody targeting ROR1. Kancera AB...
BioCentury | Oct 22, 2012
Emerging Company Profile

Sprint: Quick start in cancer

...2010, Sprint co-founded cancer company Kancera AB and out-licensed the PFKFB3 program to the newco. "Co-founding Kancera...
...will probably seek additional funding from its investors early next year. Companies and Institutions Mentioned Kancera AB...
BioCentury | Oct 8, 2012
Company News

Intellect Neurosciences, Kancera deal

...Intellect partnered with Kancera's iNovacia AB subsidiary to evaluate compounds needed to optimize Intellect's Conjumab-A...
...financial details, while Kancera could not be reached. Intellect Neurosciences Inc. (OTCBB:ILNS), New York, N.Y. Kancera AB...
Items per page:
1 - 8 of 8